ETANA DRIVES INNOVATION AND NATIONAL VACCINE INDEPENDENCE
Jakarta, June 2, 2026 - PT Etana Biotechnologies Indonesia (Etana) reaffirms its commitment to improving public health through vaccine innovation and development, with a particular focus on the Human Papillomavirus (HPV) vaccine. As a biopharmaceutical company focused on high-quality health products, Etana continues to deliver strategic solutions for cervical cancer prevention, which remains one of the leading causes of female mortality in Indonesia.
Indra Lamora, Director of the Vaccine and Anti-Infectious Business Unit at Etana, stated, "We remain committed to delivering vaccine innovations that are not only high quality but also relevant to the needs of Indonesian society. Through HPV vaccine development, local PCV-13 production, and the meningitis vaccine we have now officially launched, we want to make a real contribution to improving immunization coverage and the quality of life of the Indonesian people."
Immunization is one of the most effective public health measures for preventing infectious diseases. Etana continues to raise public awareness about the importance of immunization while supporting national vaccine self-sufficiency.
Etana has been producing the PCV-13 vaccine domestically to prevent pneumonia in children. This vaccine is now part of the Indonesian government's national immunization program, as a concrete step toward reducing childhood illness and death from pneumonia. Etana has also expanded its vaccine portfolio with the introduction of a meningitis vaccine, produced to support the immunization needs of the general public, including high-risk groups and those undertaking Hajj or Umrah pilgrimages.
Etana is committed to ensuring that every locally developed vaccine product meets Halal certification standards from the Halal Product Assurance Organizing Body (BPJPH). This addresses the specific needs of Indonesian society and broadens national acceptance of health innovations.
Successful immunization programs require cross-sector collaboration. Etana actively works with the government, healthcare workers, research institutions, and various stakeholders to ensure optimal vaccine distribution and utilization.
At every stage of development, Etana upholds global standards for product quality, safety, and efficacy, to ensure that its innovations not only meet national regulations but are also competitive at the international level.
With a long-term vision of strengthening Indonesia's biotechnology ecosystem, Etana is committed to being part of the global solution in providing vaccines that are innovative, affordable, and high quality.
About Etana
Established in 2014, Etana is an Indonesian biopharmaceutical company that researches, manufactures and markets biological therapies for the Southeast Asian market. With a mission to serve patients by providing high quality, affordable, and innovative therapies, the company has built state-of-the-art local production facility that meet international and Indonesian FDA standards. The facility are able to produce biological therapy with halal certification from the Indonesian Ulama Council (MUI). Etana aspires to become the leading biopharmaceutical company in the ASEAN region through aggressive expansion in production capacity and product development, with a primary focus on oncology and vaccine products.
Etana is led by a local management team who come from various international and domestic educational backgrounds and have strong experience in the biopharmaceutical industry and are supported by a team of international investors and leading biopharmaceutical companies. Etana aims to provide innovative yet affordable therapies through local production, to support Indonesian government programs and larger market demands. Etana is currently a leading biotech company in Indonesia committed to the research and manufacture of monoclonal antibodies, mRNAs and other biological platforms. For more information on Etana, visit: www.id.etanabiotech.com